3
Participants
Start Date
April 23, 2018
Primary Completion Date
October 13, 2020
Study Completion Date
October 13, 2020
SHP615
SHP615 oromucosal solution will be administered as a single age-specific dose (2.5, 5, 7.5 and 10 mg).
MHOS/SHP615
MHOS/SHP615
Yamanashi Prefectural Central Hospital, Kofu
Hokkaido University Hospital, Sapporo
NHO Minami-Okayama Medical Center, Okayama
Tokyo Women's Medical University Yachiyo Medical Center, Yachiyo
Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka
Fukuoka Children's Hospital(NW), Fukuoka
Gifu Prefectural General Medical Center, Gifu
NHO Hokkaido Medical Center, Hokkaidō
Kumamoto Saishunso National Hospital, Kumamoto
NHO Nagasaki Medical Center, Nagasaki
NHO Nishi Niigata Chuo National Hospital, Niigata
Okayama University Hospital, Okayama
Nakano Children's Hospital, Osaka
Osaka Women's and Children's Hospital(NW), Osaka
Aichi Children's Health and Medical Center(NW), Ōbu
Saitama Children's Medical Center(NW), Saitama
Jichi Children's Medical Center Tochigi, Saitama-shi
Osaka University Hospital, Suita
Osaka University Hospital, Yamadaoka
Tokyo Women's Medical University Hospital, Tokyo
National Center Hospital, NCNP, Tokyo
Tottori University Hospital, Tottori
Kanagawa Children's Medical Center(NW), Yokohama
Lead Sponsor
Takeda Development Center Americas, Inc.
INDUSTRY
Shire
INDUSTRY